7.1 C
New York
Wednesday, March 22, 2023

There’s No Getting Around Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Rhythm Pharmaceuticals Inc. (RYTM) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.34, or -1.40%, to $24.00. The Rhythm Pharmaceuticals Inc. has recorded 7,970 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

RYTM belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $24.34 and fluctuated between $26.48 as its day high and $24.34 as its day low. The current market capitalization of Rhythm Pharmaceuticals Inc. is $1.44B. A total of 0.68 million shares were traded on the day, compared to an average of 578.27K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RYTM has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 2,500 shares. Over the last 12 months, there were 4 BUYs and 5 SELLs from insiders. Insiders purchased 44,118 shares during that period but sold 25,464.

In the most recent transaction, Mazabraud Yann sold 1,177 shares of RYTM for 27.03 per share on Feb 14. After the transaction, the EVP, Head of International now owns 3,827 company shares. In a previous transaction on Feb 14, Smith Hunter C sold 702 shares at 26.87 per share. RYTM shares that Chief Financial Officer owns now total 59,406.

Among the insiders who sold shares, Chien Jennifer disposed of 635 shares on Feb 14 at a per-share price of $26.87. This resulted in the EVP, Head of North America holding 4,940 shares of RYTM after the transaction. In another insider transaction, Shulman Joseph sold 554 shares at $26.87 per share on Feb 14. Company shares held by the Chief Technical Officer now total 3,741.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RYTM in the last 3 months, the mean price target is $38.25 with high estimates of $52.00 and low estimates of $32.00. In terms of 52-week highs and lows, RYTM has a high of $34.99 and a low of $3.04.

As of this writing, RYTM has an earnings estimate of -$0.81 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.7 per share and a lower estimate of -$1.03. The company reported an EPS of -$0.89 in the last quarter, which was 6.30% higher than expectations of -$0.95.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RYTM is Overweight with a score of 4.17. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles